SAN DIEGO, CA - (BUSINESS WIRE) - Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, announced today that data from clinical studies on their oncolytic agent, CAL1 vaccinia virus, and stem cell delivery system will be presented…
Calidi BiotherapeuticsJune 22, 2020